Characteristics of the first 443 patients in the BSRBR-RA treated with JAKi

Ever exposed [N = 443] No biologic exposure [N = 112] Previous biologic exposure [N = 331]
Baricitinib374 (84%)103 (28%)271 (72%)
Tofacitinib69 (16%)9 (13%)60 (87%)
Age (years) 61 (53 to 69)62 (51 to 71)61 (53 to 69)
Female 335 (76%)81 (72%)254 (77%)
Disease duration (years) 12 (6 to 21)6 (3 to 15)14 (8 to 22)
Number of previous biologics--3 (2 to 4)
No prior biologics1 prior biologic>2 prior biologicsUnknown112 (25%)63 (14%)211 (48%)57 (13%)112 (100%)---0 (0%)63 (19%)211 (64%)57 (17%)
Type of previous biologic exposure---
TNF inhibitorRituximabAbataceptTocilizumab--------248 (91%)143 (52%)95 (35%)139 (51%)
Concurrent Methotrexate 185 (43%)51 (48%)134 (42%)
Concurrent oral steroids 133 (31%)22 (21%)111 (34%)
Comorbidities# ---
None1 comorbidity2+ comorbidities170 (38%)125 (28%)148 (34%)58 (52%)25 (22%)29 (26%)112 (34%)100 (30%)119 (36%)
Prior Cancer38 (9%)15 (15%)23 (7%)
Pulmonary Fibrosis11 (4%)3 (3%)8 (4%)
DAS28 5.7 (5.1 to 6.4)5.6 (5.2 to 6.2)5.8 (5.0 to 6.6)
HAQ 2 (1.4 to 2.5)1.9 (0.9 to 2.4)2.1 (1.5 to 2.6)

Results presented as N (%) or median (IQR).#Comorbidities - hypertension, ischaemic heart disease, stroke, lung disease (asthma and COPD), renal disease, diabetes, depression, liver disease.